timothy sykes logo

Stock News

Madrigal’s Surge: Breakthrough in Liver Treatment?

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Ellis Hobbs Fact-checked by Matt Monaco
Updated 7/16/2025, 2:33 pm ET 7/16/2025, 2:33 pm ET | 5 min 5 min read
Madrigal’s Surge: Breakthrough in Liver Treatment? Thumbnail

On Thursday, Madrigal Pharmaceuticals Inc. stocks have been trading up by 11.21 percent, amid innovation and analyst upgrades.

Candlestick Chart

Live Update At 14:32:50 EST: On Wednesday, July 16, 2025 Madrigal Pharmaceuticals Inc. stock [NASDAQ: MDGL] is trending up by 11.21%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Landscape: Earnings and Metrics

As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.” Success in trading requires not just skill and strategy but also a mindset of resilience and discipline. It’s essential to understand that trading isn’t about achieving a perfect win record, but rather about managing risk and capital preservation. By focusing on these principles, traders can endure market fluctuations and systematically grow their portfolios over time.

Tracing the financial pulse of Madrigal Pharmaceuticals, it displays a quirky dance between profits and losses. Their recent revenue revelation sheds light on $180.1M, paired with a market valuation that leaves some analysts scratching their heads. This revenue translates into perplex equations due to a complex interplay with a price-to-sales ratio hovering around 21.77. How does this core figure sweep over anticipated profit strides? The financial statements sing a different tune as metrics like operating cash flow dip deep into negative, tapping at -$88.9M. Could it be the result of vast investments or simply a shift in capital play?

Drilling down, their balance sheet unfolds a meticulous narrative. As of March 31, 2025, the assets piled up to approximately $996.6M, while liabilities ran a parallel marathon, amounting to $286M. Nevertheless, the legroom offered by a current ratio of 5.9 and a quick ratio flirting around 5.4 puts Madrigal on a sturdy pedestal for fulfillment short-term. Only time tells if the broader balance remains in tango.

Yet, the most concerning performance metric might be the ever-vanishing ratio of returns. A gloom strikes with return on assets registering a blunt -54.9% and a return on equity echoing a stark -76.31%. Such dismal percentages emphasize an urgent call for strategic pivots or doubling down on the resmetirom ticket.

Impact of Recent Developments

Resmetirom, Madrigal’s flagship, held the limelight after the EMA Committee poured favor over its efficacy in tackling the chronic liver disease, MASH. Suppose the drug secures approval by August. In that case, it’s poised to be the premier MASH treatment in the EU, a milestone propelling the company’s momentum. The groundbreaking MAESTRO-NASH trial yielded encouraging results, sweetening the pot for stakeholders eager to witness resmetirom’s regulatory victory.

Imagine riding the stock wave of Madrigal, where just days fluctuate between mild trepidation and projected stability. The trials echo stories of past pharmaceutical companies, where perseverance led to triumphant acclaim. As news continues buzzing from continent to continent, global sentiments may soon align with Madrigal’s trajectory.

More Breaking News

Conclusion: Final Thoughts

Madrigal’s recent news discomfortingly tilts scales either in favor of bold progress or strategic hesitation. With EMA’s burgeoning approval, what stands out is Madrigal’s potential trajectory over MASH treatments affecting stock tickers with newfound gravity. However, given the volatile undercurrent of financial metrics, stakeholders remain cautious. As millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.” This serves as a reminder to traders navigating these shifts that patience can be as prudent as bold decisions.

That fine line between calculated risks and breakthrough success may well define Madrigal’s stock future. Will its market pivotal turn evolve into a robust bullish ascend or revert to ambiguous flutter? As the calendar pages flip to August, only time and trials will reveal whether Madrigal’s bold strategies bring enormous rewards or find themselves curtailed amidst unforeseen obstacles.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”